Glucotrack, Inc.
No enriched coverage for $GCTK in the last 7 days.
No SEC Form 4 filings for $GCTK in the last 30 days.
See all $GCTK insider activity →Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. As previously disclosed, on July 14, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement as supplemented by a joinder dated August 4, 2026 (the “Purchase Agreement”), with certain investors (th
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Pricing of $3 Million Public Offering RUTHERFORD, N.J. & LA JOLLA, Calif.: Sept. 24, 2026—(BUSINESS WIRE)—Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169
Biotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
Recent GCTK coverage spans corporate actions and market movers.
The amendments tighten conversion terms and eliminate downward floor‑price adjustments, likely reducing dilution risk and supporting the stock.
The raise provides modest cash for operations but dilutes existing shareholders; short‑term price pressure likely.
Capital raise provides funding for pipeline and liquidity.
The offering raises ~$3.1 M, providing fresh capital but diluting existing shareholders.
The raise provides modest capital for ongoing R&D and may support the stock near its recent low.
AlphAI scores every news story that mentions GCTK with an AI model for sentiment and relevance, and aggregates insider trades from Glucotrack, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. As previously disclosed, on July 14, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement as supplemented by a joinder dated August 4, 2026 (the “Purchase Agreement”), with certain investors (th
1 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Pricing of $3 Million Public Offering RUTHERFORD, N.J. & LA JOLLA, Calif.: Sept. 24, 2026—(BUSINESS WIRE)—Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169
1 min readBiotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
3 min readGlucoTrack, Inc. (GCTK) rose 26.64% to $2.5717 after announcing a public offering of 169,388 shares at $2.04 each and warrants for 1,350,220 shares at $2.039 per warrant. The company expects $3.10M in gross proceeds, with the offering expected to close by September 25. Trading volume surged to 45.93M shares.
1 min readGlucotrack (GCTK) priced a public offering of 169,388 shares at $2.04 each and warrants for 1,350,220 shares at $2.039 each, expecting $3.1M gross proceeds. The offering, underwritten by Dawson James Securities, is set to close by September 25, 2026. GCTK's stock closed at $2.03 on Wednesday, up to $2.24 in pre-market trading.
1 min readGlucoTrack Inc (GCTK) shares surged 117.7% to $4.42 in pre-market trading after its subsidiary, Lokahi Therapeutics, signed its first external partnership with Innovate GBM for brain tumor research. The deal involves Lokahi's AI-driven asset-identification process.
2 min readGlucoTrack (NASDAQ:GCTK) shares rose 80.30% to $3.66 in after-hours trading after its subsidiary, Lokahi Therapeutics, signed its first external partnership with Innovate GBM for brain tumor research. The deal involves using Lokahi's AI platform to identify therapeutic assets. GlucoTrack has a market cap of $1.62M and a 52-week range of $2 to $135.75.
2 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities RUTHERFORD, N.J., and LA JOLLA, CA: Sept. 23, 2026 — Lōkahi Therapeutics™ today issued a strategic corporate update highl
1 min readPaul V. Goode resigned from Glucotrack's (GCTK) board citing potential conflict of interest related to a merger with Lokahi Therapeutics. The company completed the merger, with Lokahi securityholders receiving Glucotrack stock. Glucotrack also secured bridge financing, approved stock issuances, and received a patent for its glucose monitoring system.
1 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 14, 2026, Paul V. Goode notified the Board of Directors of Glucotrack, Inc. (the “Company”) of his resignatio
1 min read